240 related articles for article (PubMed ID: 11206962)
21. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
22. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
23. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
24. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
26. Iron burden in sickle cell anemia.
O'Brien RT
J Pediatr; 1978 Apr; 92(4):579-82. PubMed ID: 633016
[TBL] [Abstract][Full Text] [Related]
27. Liver injury is associated with mortality in sickle cell disease.
Feld JJ; Kato GJ; Koh C; Shields T; Hildesheim M; Kleiner DE; Taylor JG; Sandler NG; Douek D; Haynes-Williams V; Nichols JS; Hoofnagle JH; Jake Liang T; Gladwin MT; Heller T
Aliment Pharmacol Ther; 2015 Oct; 42(7):912-21. PubMed ID: 26235444
[TBL] [Abstract][Full Text] [Related]
28. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal MRI and Ferritin Monitoring of Iron Overload in Chronically Transfused and Chelated Children With Sickle Cell Anemia and Thalassemia Major.
Aubart M; Ou P; Elie C; Canniffe C; Kutty S; Delos V; Graffigne C; de Montalembert M; Brousse V
J Pediatr Hematol Oncol; 2016 Oct; 38(7):497-502. PubMed ID: 27548334
[TBL] [Abstract][Full Text] [Related]
30. Iron chelation therapy for patients with sickle cell disease and iron overload.
Inati A; Khoriaty E; Musallam KM; Taher AT
Am J Hematol; 2010 Oct; 85(10):782-6. PubMed ID: 20721892
[No Abstract] [Full Text] [Related]
31. Ferritin and LIC: predicting liver injury in children with sickle cell.
Smith E; Lebensburger J; Hilliard L; Kelly D; Fineberg N; Bai S; Howard T
J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):387-90. PubMed ID: 24553473
[TBL] [Abstract][Full Text] [Related]
32. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
Ault P; Jones K
Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
[TBL] [Abstract][Full Text] [Related]
33. Gaps in the diagnosis and management of iron overload in sickle cell disease: a 'real-world' report from the GRNDaD registry.
Wilson SR; Sears M; Williams E; Drapekin J; Sivakumar I; Padrino S; Desai PC; Hager W; Manwani D; Clay LJ; Field JJ; Kanter J; Cohen AJ; Saif Ur Rehman S; Lanzkron S; Little JA;
Br J Haematol; 2021 Dec; 195(5):e157-e160. PubMed ID: 34423416
[No Abstract] [Full Text] [Related]
34. Management of iron overload in hemoglobinopathies.
Allali S; de Montalembert M; Brousse V; Chalumeau M; Karim Z
Transfus Clin Biol; 2017 Sep; 24(3):223-226. PubMed ID: 28673501
[TBL] [Abstract][Full Text] [Related]
35. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Adamkiewicz TV; Abboud MR; Paley C; Olivieri N; Kirby-Allen M; Vichinsky E; Casella JF; Alvarez OA; Barredo JC; Lee MT; Iyer RV; Kutlar A; McKie KM; McKie V; Odo N; Gee B; Kwiatkowski JL; Woods GM; Coates T; Wang W; Adams RJ
Blood; 2009 Nov; 114(21):4632-8. PubMed ID: 19721013
[TBL] [Abstract][Full Text] [Related]
36. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
37. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies.
Jastaniah W; Harmatz P; Pakbaz Z; Fischer R; Vichinsky E; Walters MC
Pediatr Blood Cancer; 2008 Feb; 50(2):319-24. PubMed ID: 17557314
[TBL] [Abstract][Full Text] [Related]
38. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
Aldouri MA; Wonke B; Hoffbrand AV; Flynn DM; Laulicht M; Fenton LA; Scheuer PJ; Kibbler CC; Allwood CA; Brown D
J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
[TBL] [Abstract][Full Text] [Related]
39. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
40. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
